As the COVID-19 pandemic continues, the worldwide search for an effective treatment is still ongoing. Remdesivir and its active metabolite GS-441524 are both antiviral drugs that have been examined and partially approved for the treatment of COVID-19 due to their capability of inhibiting virus replication.
In this application note, the separation of GS-441524 and Remdesivir in only 3 minutes is shown. A YMC-Triart C18 UHPLC column provides fast and reliable results making it an ideal choice for QC purposes.
You can download the application note with the full method details here.
近期留言